

August 10, 2015



Actinium Successfully Labels Antibody with Actinium-225 For Next Entry into Pipeline

Robustness of Actinium's Technology Platform Further Validated by New Pipeline Addition

NEW YORK, NY -- (Marketwired) -- 08/10/15 -- Actinium Pharmaceuticals, Inc.(NYSE MKT: ATNM) successfully completed foundational phases of development of an antibody construct labeled with actinium-225 using the Company's novel proprietary APIT (Alpha Particle Immunotherapy Technology) platform. This new pipeline entry further validates the robustness of Actinium's platform technology. The labeled antibody has the potential to be broadly used in the field of hematology/oncology. Quality control testing of the new construct has confirmed that the product meets or exceeds all specifications related to biological integrity and properties of the labeled antibody. Early animal work has confirmed the biological properties of this new antibody drug conjugate (ADC).

Based on the successful outcome of this first phase in this new development program, collaborating parties are continuing preclinical development of the product leading to clinical trials. The Company is further evaluating biological effectiveness in appropriate animal models and also validating the clinical and market opportunity applicable to this product candidate. Assuming that the clinical and market potential of this antibody construct are confirmed, the Company expects to unveil the development plan and timing for the latest pipeline entry in the fourth quarter of 2015.

Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post surgery. "These initial results confirm that we have a very robust technology that is well protected on all sides with appropriate intellectual property," said Kaushik J. Dave, Actinium's President and CEO. "We can now continue moving forward with further development and evaluation of this latest product candidate which expands our pipeline."

About Actinium-225

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated at Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

David Gould, MD
SVP, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
dgould@actiniumpharma.com

Source: Actinium Pharmaceuticals